IP Library Granted Patent US 10,526,629
Granted Patent B2
US 10,526,629 · App. 16/432,541 · Granted Jan 7, 2020

RNA polymerase variants

Inventors: Amy E. Rabideau (Waltham, MA); Athanasios Dousis (Cambridge, MA); Kanchana Ravichandran (Cambridge, MA); Elissa Hobert (Cambridge, MA)
Assignee: ModernaTX, Inc.
C12P19/34C12N9/1247C12Y207/11023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,526,629
App. No.
16/432,541
Granted
Jan 7, 2020
Kind
B2
Abstract

The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.

Claims (14)

1. A T7 ribonucleic acid (RNA) polymerase variant comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1 modified to comprise an amino acid substitution at position G47, wherein the T7 RNA polymerase variant has RNA polymerase activity.

2. The T7 RNA polymerase variant of claim 1 , wherein the amino acid substitution is selected from the group consisting of alanine, isoleucine, leucine, methionine, lysine, glutamine, and glutamate.

3. The T7 RNA polymerase variant of claim 2 , wherein the amino acid substitution is alanine (G47A).

4. The T7 RNA polymerase variant of claim 1 , wherein the T7 RNA polymerase variant comprises an amino acid sequence having at least 95% identity to SEQ ID NO:1.

5. The T7 RNA polymerase variant of claim 1 comprising an additional C-terminal amino acid.

6. The T7 RNA polymerase variant of claim 5 , wherein the additional C-terminal amino acid comprises glycine (G).

7. The T7 RNA polymerase variant of claim 1 , wherein the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO:3.

8. The T7 RNA polymerase variant of claim 5 comprising two additional C-terminal amino acids.

9. The T7 RNA polymerase variant of claim 8 , wherein the two additional C-terminal amino acids comprise the same type of amino acid or two different types of amino acids.

10. A T7 ribonucleic acid (RNA) polymerase variant comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1 modified to comprise an alanine at position 47, wherein the T7 RNA polymerase variant has RNA polymerase activity.

11. The T7 RNA polymerase variant of claim 10 comprising the amino acid sequence of SEQ ID NO: 3.

12. The T7 RNA polymerase variant of claim 10 further comprising a C-terminal glycine.

13. The T7 RNA polymerase variant of claim 12 comprising the amino acid sequence of SEQ ID NO: 110.

14. A T7 RNA polymerase variant comprising the amino acid sequence of SEQ ID NO: 110.

Assignments (2)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2019
From: RABIDEAU, AMY E.; DOUSIS, ATHANASIOS; RAVICHANDRAN, KANCHANA; HOBERT, ELISSA
To: MODERNATX, INC.
Reel/Frame 050284/0351 →
Cited By (6)
US 12,551,734 US 12,582,609 US 12,622,960 US 12,629,412 US 12,667,543 US 12,691,177